Oryzon Genomics announced updated positive clinical data for iadademstat, an LSD1 inhibitor, in acute myeloid leukemia (AML) from two Phase Ib trials. In first-line AML treatment combined with azacitidine and venetoclax, iadademstat demonstrated a 100% overall response rate and a 93% composite complete remission rate, with a favorable safety profile and an estimated 12-month overall survival of 74%. In relapsed/refractory FLT3-mutated AML, iadademstat combined with gilteritinib showed a 67% composite complete remission rate and good safety. These results support accelerated clinical development plans and will be presented at the European Hematology Association Congress in June 2026.
Greenlight, a leading cannabis operator, expanded its Ohio presence by opening four new dispensaries and adding in-state manufacturing, reaching the state's maximum allowed eight dispensaries. This move strengthens Greenlight's position in Ohio's lim...
Halper Sadeh LLC is investigating whether shareholders of Element Solutions Inc (ESI), Crinetics Pharmaceuticals (CRNX), and Solstice Advanced Materials (SOLS) are receiving fair treatment in their respective sale and merger transactions. The firm hi...
Investment banks Scotiabank and Bernstein have lowered their price targets for Comcast due to increased competition from new players like SpaceX's Starlink and valuation risks. Comcast is also undergoing a major strategic shift by spinning off its NB...
Elevance Health reported strong Q2 2026 results with earnings per share of $7.45, surpassing analyst estimates of around $6.20. Revenue also exceeded expectations at $49.83 billion, marking consistent quarterly outperformance. The company raised its ...
Lotto.com has appointed Ruxandra Tereanu as Chief Operating Officer and Amanda Coyle as Vice President of Human Resources to strengthen its leadership team amid ongoing expansion in the US digital lottery market. Tereanu brings 13 years of experience...
